Brand-name vs compounded
Hers vs Embody: Brand-Name or Compounded? (2026)
Hers $149/mo vs Embody $69/mo. 2026 comparison of pricing, medication and support, with 12-month totals rather than first-month offers.
Published · Pricing as published in our provider dataset, synced · Editorial scores 9.8 and 7.6 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
On paper, Hers and Embody sell the same thing: a prescription, a vial and a delivery date. In practice they are priced and staffed on different assumptions.
The dividing line is regulatory, not cosmetic: Hers works with product the FDA has reviewed and approved, while Embody runs on compounded medication prepared by a pharmacy rather than manufactured under an approved application. Everything else about the two — price, support, shipping — follows from that decision.
Everything here is drawn from each provider's own published pricing and program detail, then extended into six- and twelve-month totals so the two become comparable. No number here is inferred; if a provider does not publish it, the table says so.
The short answer
- Lowest 12-month cost
- Embody — $828 against $1,788 at Hers, on each provider's own best published pricing.
- FDA-approved medication
- Hers — FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen — a finished product the FDA has reviewed, rather than a compounded preparation.
- Tirzepatide access
- Embody — Tirzepatide at $119/mo; the other side publishes semaglutide only.
- Longest public track record
- Embody — 11,250 patient reviews against 6,200.
Hers vs Embody: the specification
Read the second row before the first: the advertised price and the price you actually run at are frequently different numbers.
| Hers | Embody | |
|---|---|---|
| Advertised price | Wegovy pill from $149/mo, injectable from $199/mo | Semaglutide $69/mo (was $299), tirzepatide $119/mo |
| Rate after promotions | $149/mo | $69/mo |
| Pricing structure | Published rate per medication | Published rate per medication |
| Medication | FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen | Compounded semaglutide and compounded tirzepatide |
| Tirzepatide | Not published | $119/mo |
| Price transparency | Published upfront | Published upfront |
| Shipping | Home delivery, no insurance required | Free shipping, 1-2 day delivery after approval |
| Support model | Provider check-ins included | No coaching program stated |
| Patient reviews | 6,200 | 11,250 |
| eRxDoctor score | 9.8/10 | 7.6/10 |
The real cost: six months and twelve
Almost every complaint about telehealth GLP-1 pricing traces back to comparing month one instead of month twelve. Below, both are carried out to six and twelve months so the comparison holds at the point it matters.
| Hers | Embody | |
|---|---|---|
| First month | $149 | $69 |
| Months 2 onward | $149/mo | $69/mo |
| 6-month total | $894 | $414 |
| 12-month total | $1,788 | $828 |
| Best published plan | No multi-month discount published | No multi-month discount published |
The twelve-month spread is $960. That is the number to hold Hers against: it has to justify roughly $80 extra every month.
Brand-name product versus a pharmacy preparation
Hers supplies FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen. A brand-name GLP-1 is a finished drug the FDA has reviewed for safety, efficacy and manufacturing quality, and every vial or pen is the same product made to the same specification.
Embody supplies compounded semaglutide and compounded tirzepatide — compounded medication prepared by a pharmacy rather than manufactured under an approved application. That is what makes $69/mo possible in the first place, and it is also why the oversight is not the same.
This is the decision to make deliberately rather than by price. If the regulatory status of what you are injecting weekly matters to you, that settles it toward Hers; if cost is the barrier that has kept you from treating at all, Embody exists for a reason.
How Hers works
Hers offers FDA-approved Wegovy® (brand-name semaglutide) with a personalized care team and ongoing dose check-ins, no compounded medications.
The process is online intake with clinician review, then home delivery, no insurance required. On money, expect published rate per medication — published upfront.
Support: personalized care team with ongoing dose check-ins. The medications on offer are FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen.
Hers pros
- No insurance required
- Personalized care team with ongoing dose check-ins
- FDA-approved brand-name Wegovy®, not a compounded product
Hers cons
- Higher starting price than most compounded competitors
- No compounded/generic alternative offered
Set beside Embody, the thing to weigh: there is no compounded tier to fall back on if the brand-name price stops working for you.
Embody: what you are buying
The pitch is the lowest published semaglutide price on this list, with no lock-in. Semaglutide $69/mo (was $299), Tirzepatide $119/mo
You start with licensed provider review handled entirely online; medication arrives via free shipping, 1-2 day delivery after approval. The price behaves as published rate per medication.
24/7 support for dosing and side-effect questions. The formulary covers compounded semaglutide and compounded tirzepatide.
Embody pros
- Licensed provider review handled entirely online
- 24/7 support access for dosing and side-effect questions
- Free shipping with fast 1–2 day delivery after approval
- No long-term commitment; cancel without penalty
Embody cons
- $69 semaglutide pricing is a limited-time offer that may increase
- Final pricing may vary based on dose and clinician recommendation
- Fewer premium features (no integrated coaching or advanced monitoring) than higher-priced platforms
Against Hers specifically, the trade you are making: a limited-time rate with few of the extras that higher-priced platforms bundle.
Which one fits which patient
Choose Hers if:
- delivery works the way you want it to: home delivery, no insurance required
- the feature you would actually use: brand-name Wegovy at a price that usually buys compounded medication elsewhere
- you want an FDA-approved finished medication rather than a compounded preparation
- you want to start on their timeline: online intake with clinician review
Choose Embody if:
- what it leads on is worth paying for in your case: the lowest published semaglutide price on this list, with no lock-in
- the twelve-month total is what you are optimizing ($828 against $1,788)
- you want tirzepatide available without changing provider later
- the monthly rate is the constraint — $69/mo against $149/mo
Where each program concedes something
On price. The monthly gap is 2.2x in Embody's favor. Whether that is a saving or a false economy turns on one thing: a limited-time rate with few of the extras that higher-priced platforms bundle.
On medication. Hers covers FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen; Embody covers compounded semaglutide and compounded tirzepatide. Only Embody publishes a tirzepatide route, which matters if semaglutide underdelivers.
On clinical contact. Hers provides personalized care team with ongoing dose check-ins. Embody provides 24/7 support for dosing and side-effect questions. Both are asynchronous-first services and neither replaces a physician who can examine you.
On predictability. Both run on published rate per medication, so neither has an advantage here. The more predictable structure is worth a premium to anyone who has been surprised by a telehealth invoice before.
What the evidence actually says
Both platforms sell access to the same drug class, so the clinical record below applies equally to each.
SURMOUNT-4 found that continuing tirzepatide maintained and extended weight reduction, while withdrawing it led to substantial regain, per JAMA, SURMOUNT-4.
The SELECT trial found semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, without diabetes, per NEJM, SELECT.
None of that settles which of these two to use. It does mean the drug is doing the work, and you are choosing who supplies it and on what terms.
Hers vs Embody: common questions
Which is cheaper to start, Hers or Embody?
Embody, at $69 against $149. Note that the cheapest first month and the cheapest year are often different providers here — check the 12-month row of the cost table before deciding on the entry price.
Which costs less over a year, Hers or Embody?
Embody, at roughly $828 for twelve months against $1,788 at Hers, using each provider's own best published pricing. Those totals cover medication and program fees as published; they exclude anything a provider bills separately, and they assume you stay on the same plan for the full year.
How fast can I start with Hers compared with Embody?
Hers advertises online intake with clinician review, with home delivery, no insurance required. Embody advertises licensed provider review handled entirely online, with free shipping, 1-2 day delivery after approval. Both are subject to clinician review and to whether your state and health history clear, so treat the advertised timeline as a best case rather than a commitment.
Does Hers or Embody offer tirzepatide?
Embody does, at $119/mo. Hers publishes FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen only, so moving to tirzepatide would mean moving provider — a new intake, a new price, and the loss of any rate you had locked in.
Do Hers and Embody prescribe the same medication?
No. Hers dispenses brand-name, FDA-approved finished medication; Embody dispenses compounded medication prepared by a pharmacy rather than manufactured under an approved application. That is a regulatory difference rather than a branding one, and it is the main reason the two prices are not directly comparable.
The verdict
Embody is the cheaper year by $960, and for a straightforward course of treatment that settles it.
Where Hers justifies itself is brand-name Wegovy at a price that usually buys compounded medication elsewhere. Where it does not is anywhere the extra spend buys features you will never open.
Get the maintenance-dose price in writing from whichever one you pick. That single question prevents most of the regret in this category.
Keep comparing
- Hers vs MaximusBrand-name vs compounded
- Hers vs He & She MDBrand-name vs compounded
- Embody vs MaximusBudget vs premium
- Embody vs He & She MDBudget vs premium
- Enhance MD vs Ro.coBrand-name vs compounded
- Directmeds vs Ro.coBrand-name vs compounded
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Hers or Embody, and does not sell treatment. Read our ranking methodology.